Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents.
暂无分享,去创建一个
Shelton D Caruthers | Samuel A Wickline | Gregory M Lanza | S. Caruthers | A. Neubauer | J. D. Robertson | S. Wickline | G. Lanza | F. Hockett | R. Fuhrhop | J. Allen | J David Robertson | Anne M Neubauer | Franklin D Hockett | Tillman Cyrus | J Stacy Allen | Todd D Williams | Ralph W Fuhrhop | T. Cyrus | Todd Williams
[1] Samuel A Wickline,et al. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. , 2004, Magnetic resonance in medicine.
[2] P. Joseph,et al. In Vivo 19F NMR Imaging of the Cardiovascular System , 1985, Journal of computer assisted tomography.
[3] Z. Fayad,et al. Imaging of atherosclerosis. Coronary wall imaging with MRI. , 2002, Journal of cardiovascular risk.
[4] S A Wickline,et al. Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.
[5] Eric T Ahrens,et al. In vivo imaging platform for tracking immunotherapeutic cells , 2005, Nature Biotechnology.
[6] S. Flaim. Pharmacokinetics and side effects of perfluorocarbon-based blood substitutes. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[7] Z. Fayad,et al. Coronary Wall Imaging with MRI , 2002 .
[8] Patrick J. Gaffney,et al. Quantitative “magnetic resonance immunohistochemistry” with ligand‐targeted 19F nanoparticles , 2004 .
[9] P. Antich,et al. Regional myocardial oxygen tension: 19F MRI of sequestered perfluorocarbon , 1996, Magnetic resonance in medicine.
[10] P. Antich,et al. Regional tumor oxygen dynamics: 19F PBSR EPI of hexafluorobenzene. , 1997, Magnetic resonance imaging.
[11] W. Santamore,et al. Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? , 1988, Circulation.
[12] Donald S. Williams,et al. MRI of lungs using partial liquid ventilation with water‐in‐perfluorocarbon emulsions , 2002, Magnetic resonance in medicine.
[13] H. Kauczor,et al. 19F‐MRI of perflubron for measurement of oxygen partial pressure in porcine lungs during partial liquid ventilation , 2002, Magnetic resonance in medicine.
[14] C. Zarins,et al. Compensatory enlargement of human atherosclerotic coronary arteries. , 1987, The New England journal of medicine.
[15] L. J. Busse,et al. Deconvolution techniques for removing the effects of chemical shift in 19F nuclear magnetic resonance imaging of perfluorocarbon compounds. , 1986, Medical physics.
[16] E. Topol,et al. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease. , 1995, Circulation.
[17] Sheng-Kwei Song,et al. Improved molecular imaging contrast agent for detection of human thrombus , 2003, Magnetic resonance in medicine.
[18] K. Scheffler,et al. Principles and applications of balanced SSFP techniques , 2003, European Radiology.
[19] D Li,et al. Magnetic resonance imaging of coronary arteries. , 2001, Topics in magnetic resonance imaging : TMRI.
[20] P. Antich,et al. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging in the Dunning prostate R3327-AT1 rat tumor. , 2001, International journal of radiation oncology, biology, physics.
[21] Richard D. White,et al. Coronary imaging: angiography shows the stenosis, but IVUS, CT, and MRI show the plaque. , 2003, Cleveland Clinic journal of medicine.
[22] Shelton D Caruthers,et al. In Vitro Demonstration Using 19F Magnetic Resonance to Augment Molecular Imaging With Paramagnetic Perfluorocarbon Nanoparticles at 1.5 Tesla , 2006, Investigative radiology.
[23] Kerry K. Karukstis,et al. Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.
[24] P. Antich,et al. Tumor oxygen tension: measurement using Oxygent as a 19F NMR probe at 4.7 T. , 1994, Artificial cells, blood substitutes, and immobilization biotechnology.
[25] M. Davies,et al. Vulnerable plaque. Relation of characteristics to degree of stenosis in human coronary arteries. , 1996, Circulation.
[26] M. Graves,et al. Magnetic resonance angiography. , 1997, The British journal of radiology.
[27] B R Rosen,et al. In Vivo 19F NMR Imaging , 1985, Journal of computer assisted tomography.
[28] J. Ackerman,et al. Perfluorinated organic liquids and emulsions as biocompatible NMR imaging agents for 19F and dissolved oxygen. , 1984, Advances in experimental medicine and biology.
[29] René M. Botnar,et al. Coronary magnetic resonance angiography for the detection of coronary stenoses. , 2001, The New England journal of medicine.
[30] Valentin Fuster,et al. Intravascular Modalities for Detection of Vulnerable Plaque: Current Status , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[31] Xiaobing Fan,et al. Effect of carbogen on tumor oxygenation: combined fluorine-19 and proton MRI measurements. , 2002, International journal of radiation oncology, biology, physics.
[32] A Haase,et al. 19F‐MRI in vivo determination of the partial oxygen pressure in perfluorocarbon‐loaded alginate capsules implanted into the peritoneal cavity and different tissues , 1999, Magnetic resonance in medicine.
[33] L. Hedlund,et al. Magnetic resonance angiography with hyperpolarized 129Xe dissolved in a lipid emulsion , 1999, Magnetic resonance in medicine.
[34] L. J. Busse,et al. Deconvolution of chemical shift spectra in two- or three-dimensional [19F] MR imaging. , 1988, Journal of computer assisted tomography.